BioTuesdays

Tag - William Blair

Bionomics

Analysts start Bionomics at OW, OP

Analysts for Cantor Fitzgerald and William Blair launched coverage of Bionomics (NASDAQ:BNOX) with “overweight” and “outperform” ratings, respectively. Australia-based Bionomics is a clinical-stage biopharmaceutical...

Nkarta Therapeutics

WB starts Nkarta at OP; fair-value estimate $35

William Blair launched coverage of Nkarta (NASDAQ:NKTX) with an “outperform” rating and fair-value estimate of $35. The stock closed at $14.27 on Jan. 5. Nkarta is developing allogeneic chimeric antigen receptor (CAR)...

Cardiff Oncology

WB starts Cardiff Oncology at outperform

William Blair initiated coverage of Cardiff Oncology (NASDAQ:CRDF) with an “outperform” rating. The stock closed at $6.43 on Jan.4. Cardiff is advancing on vansertib, a specific PLK1 inhibitor, which “we view as a...

Generation Bio

WB cuts Generation Bio to market perform

William Blair downgraded Generation Bio (NASDAQ:GBIO) to “market perform,” citing variability in a non-human primate study in Factor VIII production for its hemophilia program.  In mid-morning trading, the stock was...

AugMedix

WB starts Augmedix at OP

William Blair launched coverage of Augmedix (NASDAQ:AUGX) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. Augmedix provides a virtual medical documentation and live clinical support service, which...

Tempest Therapeutics

WB starts Tempest Therapeutics at OP

William Blair initiated coverage of Tempest Therapeutics (NASDAQ:TPST) with an “outperform” rating based on the potential of the company’s three first-in-class programs, including the dual EP2/EP4 antagonist, TPST-1495...

Jasper Therapeutics

WB starts Jasper Therapeutics at OP

William Blair launched coverage of Jasper Therapeutics (NASDAQ:JSPR) with an “outperform” rating based on the potential for JSP191 to transform the bone marrow transplant field through safer and more-effective...

Eargo

WB cuts Eargo to market perform

William Blair downgraded Eargo (NASDAQ:EAR), a maker of hearing aids,  to “market perform” after the company’s 8K stated that an audit by the company’s largest third-party payer was being turned over to the U...

Assembly Biosciences

WB cuts Assembly Biosciences to MP from OP

William Blair downgraded Assembly Biosciences (NASDAQ:ASMB) to “market perform” from “outperform” after the company discontinued clinical development of ABI-H2158, its second-generation core inhibitor for the treatment...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.